Dr Jacqueline Kueh joins AUM Biosciences’ growing management team as Chief Business Officer

AUM Biosciences (AUM), a Singapore-based biotech company officially announced today that Dr Jacqueline Kueh has joined its management team as its Chief Business Officer. AUM is focused on the development of innovative and affordable oncology medicines for cancers with high unmet medical needs in Asia.

About Dr Jacqueline Kueh

An internationally trained Neuroscientist, Dr Jacqueline Kueh, has over 12 years of scientific and translational research experience under her belt. Along with this, she brings extensive fund-raising, operational (ISO) and business strategy experience to the team.

Jacqueline is passionate about translating science to benefit healthcare. She is an established strategist in early stage med- and biotech start-ups, as well as, a Venture Capitalist with late-stage due diligence expertise.

Jacqueline has been involved in venture investments and start-up commercialisation projects in London (UK) and Singapore. She has also founded 2 deep-tech start-ups in the UK, which focused mobile electronic medical records (EMR) for UK travellers, and endogenous spinal cord repair technology (Bioengineering).

“Jacqueline is one of those rare individuals who is both a talented scientist as well as being a highly successful business executive, maintaining strong links on both the science and business sides of the industry. This juxtaposition of skills makes her a very valuable and high-functioning member of the AUM executive team,” said Harish Dave, Chief Medical Officer and Co-Founder of AUM Biosciences.

Jacqueline was responsible for the commercialisation for ENDOFOTONICS, a Singapore medtech start-up developing an endoscopic device with diagnosis driven by machine learning/ AI in pre-cancer detection. In addition, she led ENDOFOTONICS’ fundraising efforts.

“ In my years of evaluating ventures, AUM has the complete ‘package’. The close-knitted founders have come together at the opportune time with the right skills and expertise, to execute AUM’s mission to address the needs of cancer markets in Asia. AUM’s vision to also use Asia as a platform for innovation in cancer drug development presents an unparalleled opportunity in surmounting impreciseness in cancer treatments that will not only benefit Asia, but globally,” said Dr Jacqueline Kueh, Chief Business Officer, AUM Biosciences

Jacqueline has also been appointed as a Community Mentor with the commercial arm of the Agency for Science, Technology and Research (A*STAR), also known as ETPL, where she shared her investment, management and operational experience with start-ups and projects. She has previously worked for University College London (UCL), UK, A*Star Genome Institute of Singapore and Institute of Molecular Biology, National University of Singapore.

Jacqueline is Dorothea Schlözer postdoctoral scholar from Germany. Her list of accolades also includes a PhD Scholarship from UCL, an MBA from the London Business School, UK, and a Monroe Brown research fellowship from the Western Michigan University, USA.

About AUM
AUM Biosciences is an oncology-focused biotechnology company that aims to accelerate the development of innovative, affordable cancer medicines for patients in Asia and around the world. AUM Biosciences focuses on early-stage development of innovative medicines for the treatment of Asian-prevalent cancers.

AUM Biosciences will have a specific focus on indications such as hepatocellular carcinoma, head and neck cancer, gastric cancer, cholangiocarcinoma, triple negative breast cancer, prostate and colorectal cancer. With a huge opportunity to identify targets for unmet medical needs, AUM Biosciences will partner and collaborate with leading research institutes, clinicians and pharmaceutical companies bringing new, affordable and effective therapies to patients in need. For more information, please visit www.aumbiosciences.com or email info@aumbiosciences.com.